As shown in Additional file 2: Figure S2, a significant increase in HER2 expression on tumor-infiltrated CD14+ and CD56+ cells was observed after administration of the anti-HER2 antibody trastuzumab to HER2+ breast cancer patients. Here, ERBB2 is linked to neoplasm.